Proton pump inhibitors (PPIs) are very effective and suitable for certain indications and treatment periods, but there is an increasing trend towards “off-label” prescriptions. To ensure that temporary administration for a specific indication does not become an unreflected permanent medication, North American experts have summarized ten best practice recommendations to help decide whether discontinuation (“deprescribing”) of PPIs could be an option to consider.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- Myelofibrosis
New findings on the role of inflammation in pathogenesis
- Incretin mimetics for obesity and prediabetes
Liraglutide, semaglutide and tirzepatide: considerable evidence base
- Treatment of infected wounds and wounds at risk of infection
Focus on an interdisciplinary perspective
- Chronic and hard-to-heal wounds
Benefit from the advantages of outpatient negative pressure wound therapy
- COPD
Even a single moderate exacerbation can be a predictor of mortality
- HER2+ metastatic breast cancer
New therapeutic standards with SHR-A 1811
- Angina tonsillaris: clinical management
Conservative therapy or surgery?
- Dermocosmetic for mild to moderate acne